Chemical leukoderma can mimic the appearance of vitiligo, particularly when the loss of skin pigmentation involves areas distant from the application site.
Monitor for signs of skin depigmentation, and advise patients to immediately inform their healthcare provider if changes in skin pigmentation occur. This subject experienced erythema and edema at DAYTRANA application sites with concurrent urticarial lesions on the abdomen and legs resulting in treatment discontinuation. This subject was not transitioned to oral methylphenidate.
However, contact sensitization should be suspected if erythema is accompanied by evidence of a more intense local reaction edema, papules, vesicles that does not significantly improve within 48 hours or spreads beyond the patch site. Confirmation of a diagnosis of contact sensitization allergic contact dermatitis may require further diagnostic testing.
Patients sensitized from use of DAYTRANA, as evidenced by development of an allergic contact dermatitis, may develop systemic sensitization or other systemic reactions if methylphenidate-containing products are taken via other routes, e.
Manifestations of systemic sensitization may include a flare-up of previous dermatitis or of prior positive patch-test sites, or generalized skin eruptions in previously unaffected skin. Other systemic reactions may include headache, fever, malaise, arthralgia, diarrhea, or vomiting.
Patients who develop contact sensitization to DAYTRANA and require oral treatment with methylphenidate should be initiated on oral medication under close medical supervision. Difficulties with accommodation and blurring of vision have been reported with stimulant treatment. Patients should be advised to avoid exposing the DAYTRANA application site to direct external heat sources, such as hair dryers, heating pads, electric blankets, heated water beds, etc.
The temperature-dependent increase in methylphenidate absorption can be greater than 2-fold [ see Clinical Pharmacology This increased absorption can be clinically significant and can result in overdose of methylphenidate [ see Overdosage 10 ].
Periodic CBC, differential, and platelet counts are advised during prolonged therapy. Detailed information on serious and adverse reactions of particular importance is provided in the Boxed Warning and Warnings and Precautions 5 sections:.
The 1, child and adolescent subjects aged years were evaluated in 10 controlled clinical studies, 7 open-label clinical studies, and 5 clinical pharmacology studies.
In the data presented below, the adverse reactions reported during exposure were obtained primarily by general inquiry at each visit, and were recorded by the clinical investigators using terminology of their own choosing.
Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of events into a smaller number of standardized event categories.
Throughout this section adverse reactions reported are events that were considered to be reasonably associated with the use of DAYTRANA based on comprehensive assessment of the available adverse event information. Further, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In a 7-week double-blind, parallel-group, placebo-controlled study in children with ADHD conducted in the outpatient setting, 7.
In a 7-week double-blind, parallel-group, placebo-controlled study in adolescents with ADHD conducted in the outpatient setting, 5. In addition to the most commonly reported adverse reactions presented in Table 2, the majority of subjects in those studies had minimal to definite skin erythema at the patch application site. This erythema generally caused no or minimal discomfort and did not usually interfere with therapy or result in discontinuation from treatment.
Erythema is not by itself a manifestation of contact sensitization. However, contact sensitization should be suspected if erythema is accompanied by evidence of a more intense local reaction edema, papules, vesicles that does not significantly improve within 48 hours or spreads beyond the patch site [ see Warnings and Precautions 5.
Overall, in these studies, A total of 30 subjects 9. Other than application site reactions, affect lability 5 subjects, 1. A total of 9 subjects 5. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to DAYTRANA exposure.
Eye Disorders: visual disturbances, blurred vision, mydriasis, and accommodation disorder. General Disorders and Administration Site Disorders : fatigue, application site reactions such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, scab, swelling, ulcer, urticaria, vesicles, and warmth.
Immune System Disorders: hypersensitivity reactions including generalized erythematous and urticarial rashes, allergic contact dermatitis, angioedema, and anaphylaxis. Nervous System Disorders : convulsion, dyskinesia, lethargy, somnolence, serotonin syndrome in combination with serotonergic drugs, and extrapyramidal disorder. Psychiatric Disorders : depression, hallucination, nervousness, and libido changes.
Nervousness and insomnia are the most common adverse reactions reported with other methylphenidate products. In children, loss of appetite, abdominal pain, weight loss during prolonged therapy, insomnia, and tachycardia may occur more frequently; however, any of the other adverse reactions listed below may also occur.
Cardiac Disorders: angina, arrhythmia, and pulse increased or decreased. Immune System Disorders: hypersensitivity reactions including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura.
Metabolism and Nutrition Disorders: anorexia and weight loss during prolonged therapy. Nervous System Disorders: drowsiness, rare reports of Tourette's syndrome and toxic psychosis. Very rare reports of neuroleptic malignant syndrome NMS have been received, and, in most of these, patients were concurrently receiving therapies associated with NMS. In a single report, a ten-year-old boy who had been taking methylphenidate for approximately 18 months experienced an NMS-like event within 45 minutes of ingesting his first dose of venlafaxine.
It is uncertain whether this case represented a drug-drug interaction, a response to either drug alone, or some other cause. Although a definite causal relationship has not been established, the following have been reported in patients taking methylphenidate:. Hepatobiliary Disorders: abnormal liver function, ranging from transaminase elevation to severe hepatic injury. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure [ see Contraindications 4.
Monitor blood pressure and adjust the dosage of the antihypertensive drug as needed [ see Warnings and Precautions 5. Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants e. Downward dose adjustments of these drugs may be required when given concomitantly with methylphenidate. It may be necessary to adjust the dosage and monitor plasma drug concentrations or, in the case of coumarin, coagulation times , when initiating or discontinuing methylphenidate.
Combined use of methylphenidate with risperidone when there is a change in dosage, whether an increase or decrease, of either or both medications, may increase the risk of extrapyramidal symptoms EPS. Monitor for signs of EPS. Published studies and post-marketing reports on methylphenidate use during pregnancy are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
There are risks to the fetus associated with the use of central nervous system CNS stimulants during pregnancy see Clinical Considerations. No effects on morphological development were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis. When methylphenidate was administered orally to rats throughout pregnancy and lactation, offspring growth and survival were decreased at maternally toxic doses see Data.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U. Animal reproduction toxicity studies with transdermal methylphenidate have not been performed. Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.
There are no reports of adverse effects on the breastfed infant and no effects on milk production. Long-term neurodevelopmental effects on infants from stimulant exposure are unknown.
Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain. Long-term effects of methylphenidate in children have not been well established. Children who are not growing or gaining weight as expected may need to have their treatment interrupted [ see Warnings and Precautions 5. Rats treated with methylphenidate early in the postnatal period through sexual maturation demonstrated a decrease in spontaneous locomotor activity in adulthood.
A deficit in acquisition of a specific learning task was observed in females only. Studies with transdermal methylphenidate have not been performed in juvenile animals. The clinical significance of the long-term behavioral effects observed in rats is unknown.
See warning containing drug abuse information [ see Boxed Warning ]. For information call Please see our Privacy Policy for more information. Please be advised that Noven has no control over the content or presentation of the site you are about to view. Click the "Continue" button to proceed. Serious heart problems have been reported with the DAYTRANA patch or other stimulant medicines including: sudden death in people with heart problems or heart defects stroke and heart attack in adults increased blood pressure and heart rate Tell the doctor if your child or a family member has any heart problems, heart defects, or increased blood pressure and heart rate.
Serious mental psychiatric problems have been reported with the DAYTRANA patch or other stimulant medicines including: new or worse aggressive behavior, hostility, anger or irritability new or worse bipolar illness or mania an extreme increase in activity or talking new or worse psychosis hearing or seeing things that are not real, being suspicious, or distrustful, believing things that are not true other unusual or extreme changes in behavior or mood Tell the doctor about any mental problems your child or family members have experienced including suicide or depression, bipolar illness, mania, or psychosis.
Be sure to tell the doctor if your child is pregnant or breast feeding. Or anything likes that! Well this has been fun! Thank you, And Good Night!!
However, I have not yet moved. Thanks Good Night. My I wake to live another day! So that I may take this experience and store it away, for when I have an urge to use any stimulant again.
Seeing as how I accidentally, closed out of the window! Perhaps, that this time, I will be able to say what I actually mean, without sounding like a raving lunatic! Well this experience has certainly humbled me, to the fact that once you start down that path, it was a long dark path, it is very difficult, to make it back to the side, upon which, there is light, and happiness, and sanity.
Beautiful sanity. Was I blessed with a second chance? To fix things? To keep up on the road that me getting caught smoking weed, has put me on? And that brings joy to me, it brings joy to my tired mind and sore body, and now at last, I shall have sleep, beautiful, blissful worriless sleep. After eating the entire brownie, I was sitting at my computer surfing the internet.
I began to feel very strange, and felt a compulsion to start describing how I felt in a text document.
Alas, it seems that I didn't save the file.
0コメント